Treatment options for chronic myeloid leukemia[J] . Maria Florencia Tanaka,Hagop Kantarjian,Jorge Cortes,Maro Ohanian,Elias Jabbour.Expert Opinion on Pharmacotherapy . 2012 (6)Tanaka, M.F. , Kantarjian, H. , Cortes, J. , Ohanian, M. & Jabbour, E. ( 2012 ) Treatment options for chronic...
Chronic myeloid leukemia (CML) occurs most often in people between ages 25 and 60. In CML, the abnormal cells are a type of blood cell called myeloid cells. CML usually involves a defective string of DNA called the Philadelphia chromosome. (This disease is not inherited; the change in DNA...
There are various subtypes of chronic leukemia, the two most common beingchronic myeloid leukemia (CML)andchronic lymphocytic leukemia (CLL). In CML, immature myeloid cells (cells that are responsible for creating red blood cells, platelets and certain white blood cells...
The choice of primary treatment for patients with chronic myeloid leukemia (CML) diagnosed in chronic phase has become exceedingly difficult. There is little doubt that allogeneic stem cell transplantation can eradicate the leukemia and that a graft-versus-leukemia effect makes a major contribution to...
Leukemias are cancers of the blood cells. Chronic myelogenous leukemia (CML) is an uncommon type of cancer of the bone marrow, which produces blood cells. "Myelogenous" refers to the type of blood cells this leukemia affects. "Chronic" means this cancer is more slowly progressing than other ...
Treatment options for chronic myeloid leukemia INTRODUCTION: The bcr-abl tyrosine kinase inhibitors (TKIs) are the cornerstone treatment for chronic myeloid leukemia (CML). However, there are many topic... MF Tanaka,H Kantarjian,J Cortes,... - 《Expert Opinion on Pharmacotherapy》 被引量: 60发...
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: Results of a phase 2 study 2002, Blood Show abstract Natural products in anticancer therapy 2001, Current Opinion in Pharmacology Show abstract Approval summary for imatinib mesylate ...
EP: 3.Frontline Treatment Options in Chronic Lymphocytic Leukemia EP: 4.BTK Inhibitors in Treatment of Chronic Lymphocytic Leukemia EP: 5.Clinical Trials With BTK Inhibitors in Chronic Lymphocytic Leukemia EP: 6.Acalabrutinib in the Treatment of Chronic Lymphocytic Leukemia EP: 7.A Look at the ...
Hehlmann R, Jung-Munkwitz S, Saussele S. Treatment of chronic myeloid leukemia when imatinib fails. Expert Opin Pharmacother. 2011 Feb; 12 (2):269–83.Hehlmann R, Jung-Munkwitz S, Saussele S. Treatment of chronic myeloid leukemia when ima- tinib fails. Expert Opin Pharmacother. 2011;...
This 45-page report provides a behind-the-scenes look at the treatment experience for those living with Chronic Myeloid Leukemia (CML). Using detailed quantitative data, it gives a full picture of the CML treatment story -...